Publications by authors named "Daniela Buglio"

Claim this Profile
S
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Daniela Buglio

Lancet Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Daniela Buglio

Haematologica· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment.
Olga Frolova, Ismael Samudio, Juliana Maria Benito, Rodrigo Jacamo, Steven M Kornblau, Daniela Buglio

Cancer Biol Ther· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Essential role of TAK1 in regulating mantle cell lymphoma survival.
Daniela Buglio, Sangeetha Palakurthi, Kate Byth, Francisco Vega, Dorin Toader

Blood· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
Manuela Lemoine, Enrico Derenzini, Daniela Buglio, L Jeffrey Medeiros, R Eric Davis

Blood· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Anas Younes, Yasuhiro Oki, R Gregory Bociek, John Kuruvilla, Michelle Fanale, Daniela Buglio

Lancet Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Adám Jóna, Noor Khaskhely, Daniela Buglio, Jessica A Shafer, Enrico Derenzini

Exp Hematol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.
Daniela Buglio, Noor M Khaskhely, Kui Shin Voo, Hector Martinez-Valdez, Yong-Jun Liu

Blood· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors in Hodgkin lymphoma.
Daniela Buglio, Anas Younes

Invest New Drugs· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Daniela Buglio, Vidya Mamidipudi, Noor M Khaskhely, Helen Brady, Carla Heise

Br J Haematol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors in lymphoma.
Amanda Copeland, Daniela Buglio, Anas Younes

Curr Opin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Annunziata Gloghini, Daniela Buglio, Noor M Khaskhely, Georgios Georgakis, Robert Z Orlowski

Br J Haematol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines.
Daniela Buglio, Georgios V Georgakis, Shino Hanabuchi, Kazuhiko Arima, Noor M Khaskhely

Blood· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma.
Victor Y Yazbeck, Daniela Buglio, Georgios V Georgakis, Yang Li, Eiji Iwado

Exp Hematol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel small-molecule therapy of Hodgkin lymphoma.
Daniela Buglio, Georgios Georgakis, Anas Younes

Expert Rev Anticancer Ther· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis